$22 Mln
$-6 Mln
--
As on 29-Sep-2023 16:00 EDT
$0.01
•
2.03%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
| -33.80 | -20.24 | -33.80 | -40.36 | -76.45 | -69.07 | -- |
|
S&P BSE Sensex
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
| -53.27 | -94.12 | 355.24 | -93.51 | -19.81 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Forte Biosciences Inc. (FBRX) stood at $ 40 Mln as on 31-Mar-23
The share price of Forte Biosciences Inc. (FBRX) is $0.662000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. Forte Biosciences Inc. (FBRX) has given a return of -76.45% in the last 3 years.
Forte Biosciences Inc. (FBRX) has a market capitalisation of $ 22 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Forte Biosciences Inc. (FBRX) is 0.49 times as on 02-Jun-2023, a -0.81% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Forte Biosciences Inc. (FBRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Forte Biosciences Inc. (FBRX) and enter the required number of quantities and click on buy to purchase the shares of Forte Biosciences Inc. (FBRX).
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
The CEO & director of Dr. Paul A. Wagner Ph.D.. is Forte Biosciences Inc. (FBRX), and CFO & Sr. VP is Mr. Antony A. Riley CPA.
The promoters of Forte Biosciences Inc. (FBRX) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
498
|
|
|
497
|
|
|
392
|
|
|
383
|
| Forte Biosciences Inc. (FBRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-47.4
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Forte Biosciences Inc. (FBRX) was $-6 Mln.
$21.58 Mln
$0.00 Mln
$-6.44 Mln
$35.90 Mln
$0.00 Mln
Moderate
$0.63 - 1.29
21,051,200
NASDAQ: FBRX
Dallas, TX
https://www.fortebiorx.com
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is... headquartered in Dallas, Texas. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
